Oyunbileg Magvanjav, MD, PhD
InstructorAbout
Research
Publications
2025
Iodine for the Outpatient Management of Graves’ Disease: A Case Series of 7 Patients
Magvanjav O, MacLeod R, Balasubramanian P, Mekala K, Peter P, Inzucchi S, Majumdar S. Iodine for the Outpatient Management of Graves’ Disease: A Case Series of 7 Patients. AACE Endocrinology And Diabetes 2025, 13: 83-87. PMID: 41641309, PMCID: PMC12866150, DOI: 10.1016/j.aed.2025.10.015.Peer-Reviewed Original ResearchTreatment of Extraosseous Giant Cell Tumor of Bone and Calcitriol-Mediated Hypercalcemia With Denosumab in Paget Disease
Magvanjav O, Bergwitz C. Treatment of Extraosseous Giant Cell Tumor of Bone and Calcitriol-Mediated Hypercalcemia With Denosumab in Paget Disease. JCEM Case Reports 2025, 3: luaf031. PMID: 40110572, PMCID: PMC11920620, DOI: 10.1210/jcemcr/luaf031.Peer-Reviewed Original Research
2019
Combination Antihypertensive Therapy Prescribing and Blood Pressure Control in a Real-World Setting
Magvanjav O, Cooper-Dehoff R, McDonough C, Gong Y, Hogan W, Johnson J. Combination Antihypertensive Therapy Prescribing and Blood Pressure Control in a Real-World Setting. American Journal Of Hypertension 2019, 33: 316-324. PMID: 31853537, PMCID: PMC7109351, DOI: 10.1093/ajh/hpz196.Peer-Reviewed Original Research
2018
Antihypertensive therapy prescribing patterns and correlates of blood pressure control among hypertensive patients with chronic kidney disease
Magvanjav O, Cooper‐DeHoff R, McDonough C, Gong Y, Segal M, Hogan W, Johnson J. Antihypertensive therapy prescribing patterns and correlates of blood pressure control among hypertensive patients with chronic kidney disease. Journal Of Clinical Hypertension 2018, 21: 91-101. PMID: 30427124, PMCID: PMC6329007, DOI: 10.1111/jch.13429.Peer-Reviewed Original ResearchAdrenergic beta-AntagonistsAgedAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBlack or African AmericanBlood PressureCase-Control StudiesComorbidityDiureticsDrug CombinationsFemaleHumansHypertensionHypertension, MalignantMaleMiddle AgedProteinuriaRenal Insufficiency, ChronicRisk FactorsUnited StatesGenetic Variants Influencing Plasma Renin Activity in Hypertensive Patients From the PEAR Study (Pharmacogenomic Evaluation of Antihypertensive Responses)
McDonough C, Magvanjav O, Sá A, El Rouby N, Dave C, Deitchman A, Kawaguchi-Suzuki M, Mei W, Shen Y, Singh R, Solayman M, Bailey K, Boerwinkle E, Chapman A, Gums J, Webb A, Scherer S, Sadee W, Turner S, Cooper-DeHoff R, Gong Y, Johnson J. Genetic Variants Influencing Plasma Renin Activity in Hypertensive Patients From the PEAR Study (Pharmacogenomic Evaluation of Antihypertensive Responses). Circulation Genomic And Precision Medicine 2018, 11: e001854. PMID: 29650764, PMCID: PMC5901893, DOI: 10.1161/circgen.117.001854.Peer-Reviewed Original Research
2017
Genetic Variants Associated With Uncontrolled Blood Pressure on Thiazide Diuretic/β‐Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) and INVEST (International Verapamil‐SR Trandolapril Study) Trials
Magvanjav O, Gong Y, McDonough C, Chapman A, Turner S, Gums J, Bailey K, Boerwinkle E, Beitelshees A, Tanaka T, Kubo M, Pepine C, Cooper‐DeHoff R, Johnson J. Genetic Variants Associated With Uncontrolled Blood Pressure on Thiazide Diuretic/β‐Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) and INVEST (International Verapamil‐SR Trandolapril Study) Trials. Journal Of The American Heart Association 2017, 6: e006522. PMID: 29097388, PMCID: PMC5721751, DOI: 10.1161/jaha.117.006522.Peer-Reviewed Original ResearchAdolescentAdrenergic beta-AntagonistsAdultAgedAldehyde Dehydrogenase 1 FamilyAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsAtenololBlood PressureCalcium Channel BlockersChi-Square DistributionDrug CombinationsDrug ResistanceFemaleFloridaGenome-Wide Association StudyGeorgiaHumansHydrochlorothiazideHypertensionIndolesLogistic ModelsMaleMiddle AgedMultivariate AnalysisOdds RatioPharmacogeneticsPharmacogenomic VariantsPolymorphism, Single NucleotideProspective StudiesRetinal DehydrogenaseRisk FactorsSodium Chloride Symporter InhibitorsTreatment OutcomeVasodilator AgentsVerapamilYoung AdultMultisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention
Cavallari L, Lee C, Beitelshees A, Cooper-DeHoff R, Duarte J, Voora D, Kimmel S, McDonough C, Gong Y, Dave C, Pratt V, Alestock T, Anderson R, Alsip J, Ardati A, Brott B, Brown L, Chumnumwat S, Clare-Salzler M, Coons J, Denny J, Dillon C, Elsey A, Hamadeh I, Harada S, Hillegass W, Hines L, Horenstein R, Howell L, Jeng L, Kelemen M, Lee Y, Magvanjav O, Montasser M, Nelson D, Nutescu E, Nwaba D, Pakyz R, Palmer K, Peterson J, Pollin T, Quinn A, Robinson S, Schub J, Skaar T, Smith D, Sriramoju V, Starostik P, Stys T, Stevenson J, Varunok N, Vesely M, Wake D, Weck K, Weitzel K, Wilke R, Willig J, Zhao R, Kreutz R, Stouffer G, Empey P, Limdi N, Shuldiner A, Winterstein A, Johnson J, Network I. Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. JACC Cardiovascular Interventions 2017, 11: 181-191. PMID: 29102571, PMCID: PMC5775044, DOI: 10.1016/j.jcin.2017.07.022.Peer-Reviewed Original ResearchAgedClinical Decision-MakingClopidogrelCytochrome P-450 CYP2C19Drug ResistanceFemaleHumansMaleMiddle AgedPatient SelectionPercutaneous Coronary InterventionPharmacogeneticsPharmacogenomic TestingPharmacogenomic VariantsPlatelet Aggregation InhibitorsPrasugrel HydrochloridePredictive Value of TestsRisk AssessmentRisk FactorsTicagrelorTime FactorsTreatment OutcomeUnited StatesPharmacogenetic Associations of β1-Adrenergic Receptor Polymorphisms With Cardiovascular Outcomes in the SPS3 Trial (Secondary Prevention of Small Subcortical Strokes)
Magvanjav O, McDonough C, Gong Y, McClure L, Talbert R, Horenstein R, Shuldiner A, Benavente O, Mitchell B, Johnson J. Pharmacogenetic Associations of β1-Adrenergic Receptor Polymorphisms With Cardiovascular Outcomes in the SPS3 Trial (Secondary Prevention of Small Subcortical Strokes). Stroke 2017, 48: 1337-1343. PMID: 28351962, PMCID: PMC5404951, DOI: 10.1161/strokeaha.116.015936.Peer-Reviewed Original Research
2012
Gene-environment interactions and obesity traits among postmenopausal African-American and Hispanic women in the Women’s Health Initiative SHARe Study
Velez Edwards D, Naj A, Monda K, North K, Neuhouser M, Magvanjav O, Kusimo I, Vitolins M, Manson J, O’Sullivan M, Rampersaud E, Edwards T. Gene-environment interactions and obesity traits among postmenopausal African-American and Hispanic women in the Women’s Health Initiative SHARe Study. Human Genetics 2012, 132: 323-336. PMID: 23192594, PMCID: PMC3704217, DOI: 10.1007/s00439-012-1246-3.Peer-Reviewed Original ResearchAgedAlcohol DrinkingBlack or African AmericanBody Mass IndexEnergy IntakeFemaleGene-Environment InteractionGenetic Predisposition to DiseaseGenome-Wide Association StudyHispanic or LatinoHumansLogistic ModelsMiddle AgedMotor ActivityObesityPolymorphism, Single NucleotidePostmenopauseProspective StudiesRisk FactorsSmokingUnited StatesWaist-Hip RatioWomen's HealthSibling composition and children's anthropometric indicators of nutritional status: Evidence from native Amazonians in Bolivia
Magvanjav O, Undurraga E, Eisenberg D, Zeng W, Dorjgochoo T, Leonard W, Team T, Godoy R. Sibling composition and children's anthropometric indicators of nutritional status: Evidence from native Amazonians in Bolivia. Annals Of Human Biology 2012, 40: 23-34. PMID: 23095024, DOI: 10.3109/03014460.2012.728621.Peer-Reviewed Original Research